Cyclacel Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCCP) is a clinical-stage biopharmaceutical company developing innovative cancer medicines targeting cell cycle control, transcriptional regulation, epigenetics, and mitosis biology for oncology and hematology indications including solid tumors and hematological malignancies; its pipeline features fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, among other small-molecule candidates designed to induce cell cycle arrest and apoptosis in cancer cells. Founded in 1996 and headquartered in Berkeley Heights, New Jersey, the company operates primarily in the United States with research ties to Dundee, Scotland, and advances precision medicine approaches by selecting patients based on biomarkers such as CDKN2A alterations. In 2025, Cyclacel executed a share exchange agreement with FITTERS Diversified Berhad, acquiring Fitters Sdn. Bhd. as a wholly-owned subsidiary to diversify into fire protection products and services including fire equipment, foam systems, fire-resistant doors, personal protective equipment, and waste-to-resource operations in Malaysia, with an amended deal adding $1 million cash consideration and extending closing to September 2025 pending approvals; the entity rebranded to Bio Green Med Solution, Inc., expanding geographically while retaining its biopharma focus.
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
Cyclacel Pharmaceuticals Announces Stock Split
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule